Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Vistusertib
Cat. No.:
OB0225LY-0305
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by HPLC.
Size:
Product Overview
Description:
Vistusertib is a small molecule inhibitor that targets the mTOR pathway with potential anti-tumor properties.
Synonym:
AZD2014; 1009298-59-2; AZD-2014; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; 3-(2,4-Bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide
CAS No.:
1009298-59-2
Compound CID:
25262792
Formula:
C25H30N6O3
Formula Weight:
462.54
Specification
Relative Density:
1.231 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Vistusertibt can be used in cancer research or play an important role in studies related to cell proliferation and metabolism.
Library Information
Targets:
PI3K/Akt/mTOR pathway
Receptors:
mTOR; P-Akt (S473); PI3Kα; pS6 (S235/236)
Pathways:
Autophagy; Apoptosis; PI3K/Akt/mTOR signaling; Cytoskeletal signaling; MAPK
Plate Number:
AOCL-4
Plate Location:
h7
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
36 mg/mL; 77.8 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
ALogP:
3.103
HBA_Count:
6
HBD_Count:
1
Rotatable Bond:
4
